

Timothy A Yap

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3426964/publications.pdf>

Version: 2024-02-01

102
papers

11,206
citations

87723

38
h-index

35952

97
g-index

103
all docs

103
docs citations

103
times ranked

15654
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	0.9	1
2	A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. <i>Annual Review of Medicine</i> , 2022, 73, 231-250.	5.0	11
3	Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. <i>JCO Precision Oncology</i> , 2022, 6, e2100456.	1.5	11
4	Precision Combination Therapies Based on Recurrent Oncogenic Coalterations. <i>Cancer Discovery</i> , 2022, 12, 1542-1559.	7.7	17
5	IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin and paclitaxel, with or without bevacizumab in patients with advanced cancer. , 2022, 10, e003924.		8
6	First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. <i>Clinical Cancer Research</i> , 2022, 28, 3695-3708.	3.2	26
7	Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. <i>JAMA Network Open</i> , 2022, 5, e2213070.	2.8	21
8	Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. <i>Current Opinion in Oncology</i> , 2022, 34, 559-569.	1.1	6
9	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2021, 11, 80-91.	7.7	148
10	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1267-1277.	3.2	21
11	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	1.5	7
12	The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. <i>British Journal of Cancer</i> , 2021, 124, 857-859.	2.9	26
13	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. <i>Cancer Discovery</i> , 2021, 11, 92-107.	7.7	36
14	The promise of DNA damage response inhibitors for the treatment of glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab015.	0.4	16
15	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 298-301.	5.1	11
16	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3050-3060.	3.2	24
17	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
18	Precision Medicine in Oncology—Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations. <i>JAMA Oncology</i> , 2021, 7, 507.	3.4	13

#	ARTICLE	IF	CITATIONS
19	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 520-527.	2.9	37
20	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 613-621.	5.2	44
21	ATR Inhibition Induces CDK1-Dependent SPOC Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4898-4909.	3.2	66
22	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. <i>Clinical Cancer Research</i> , 2021, 27, 5213-5224.	3.2	53
23	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2021, 12, 4626.	5.8	31
24	Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1825-1837.	0.9	11
25	Global Implementation of Precision Oncology. <i>JCO Precision Oncology</i> , 2021, 5, 854-858.	1.5	5
26	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1105-1124.	1.1	26
27	Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 5572-5581.	0.4	75
28	First-In-Human Phase I Study of a Next-Generation, Oral, TGF β 2 Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6666-6676.	3.2	27
29	Targeting the replication stress response through synthetic lethal strategies in cancer medicine. <i>Trends in Cancer</i> , 2021, 7, 930-957.	3.8	48
30	Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. <i>Trends in Cancer</i> , 2021, 7, 958-970.	3.8	18
31	DNA Damage Response. , 2021, , 1-12.		0
32	Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1517-1535.	0.4	9
33	DNA Damage Response. , 2021, , 536-547.		0
34	Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development. <i>Frontiers in Oncology</i> , 2021, 11, 695936.	1.3	17
35	Development of Next-Generation Poly(ADP-Ribose) Polymerase Selective Inhibitors. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 521-528.	1.0	10
36	The National Lung Matrix Trial of personalized therapy in lung cancer. <i>Nature</i> , 2020, 583, 807-812.	13.7	96

#	ARTICLE	IF	CITATIONS
37	Clinical <i>BRCA1/2</i> Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. <i>Cancer Discovery</i> , 2020, 10, 1475-1488.	7.7	109
38	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non- <i>BRCA1/2</i> -Mutant Cancers. <i>Cancer Discovery</i> , 2020, 10, 1528-1543.	7.7	82
39	Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. <i>Gynecologic Oncology</i> , 2020, 158, 570-575.	0.6	43
40	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3195-3204.	0.8	152
41	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
42	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 5951-5966.	3.9	72
43	The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 157-164.	0.6	2
44	PARP inhibition – opportunities in pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 595-596.	12.5	19
45	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7331-7339.	3.2	110
46	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. <i>Cancer Cell</i> , 2019, 35, 851-867.e7.	7.7	156
47	The DNA Damaging Revolution: PARP Inhibitors and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 185-195.	1.8	144
48	PARP Inhibitors: Extending Benefit Beyond <i>BRCA</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 3759-3771.	3.2	265
49	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. <i>Cancer Research</i> , 2019, 79, 311-319.	0.4	404
50	State-of-the-art strategies for targeting the DNA damage response in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 81-104.	12.5	736
51	Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3014-3014.	0.8	50
52	PIPA: A phase Ib study of selective γ -isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselelisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers – Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3087-3087.	0.8	4
53	Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2669-TPS2669.	0.8	10
54	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. <i>Clinical Cancer Research</i> , 2018, 24, 2719-2731.	3.2	54

#	ARTICLE	IF	CITATIONS
55	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. <i>Cancer Cell</i> , 2018, 33, 401-416.e8.	7.7	215
56	Precision oncology: East meets West. <i>International Journal of Cancer</i> , 2018, 142, 1734-1737.	2.3	1
57	Moving Precision Oncology Forward Amid Myths and Misconceptions. <i>JAMA Oncology</i> , 2018, 4, 1788.	3.4	2
58	Development of PARP and Immune-Checkpoint Inhibitor Combinations. <i>Cancer Research</i> , 2018, 78, 6717-6725.	0.4	155
59	Challenges with biomarkers in cancer drug discovery and development. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 685-690.	2.5	28
60	Combination Drug Development in BRAF Mutant Colorectal Cancer. <i>Oncoscience</i> , 2018, 5, 51-53.	0.9	1
61	Circulating tumor DNA—From bench to bedside. <i>Current Problems in Cancer</i> , 2017, 41, 212-221.	1.0	2
62	Targeting ATR in cancer medicine. <i>Current Problems in Cancer</i> , 2017, 41, 302-315.	1.0	43
63	Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. <i>Cancer Discovery</i> , 2017, 7, 558-560.	7.7	25
64	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2017, 77, 813-827.	4.9	42
65	Precision medicine in oncology. <i>Current Problems in Cancer</i> , 2017, 41, 163-165.	1.0	5
66	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. <i>Radiology</i> , 2017, 284, 88-99.	3.6	45
67	Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 20-37.	7.7	488
68	Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. <i>Current Problems in Cancer</i> , 2017, 41, 111-124.	1.0	37
69	Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 12-14.	0.5	9
70	Emerging biomarkers for PD-1 pathway cancer therapy. <i>Biomarkers in Medicine</i> , 2017, 11, 53-67.	0.6	11
71	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6468-6477.	3.2	48
72	Development of Molecularly Driven Targeted Combination Strategies. <i>Oncologist</i> , 2017, 22, 1421-1423.	1.9	4

#	ARTICLE	IF	CITATIONS
73	Precision Medicine: Progress, Pitfalls, and Promises. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2641-2644.	1.9	7
74	Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2017, 70, 12-21.	1.3	36
75	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 25-40.	4.0	87
76	Combining Molecularly Targeted Agents: Is More Always Better?. <i>Clinical Cancer Research</i> , 2017, 23, 1123-1125.	3.2	6
77	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 39.	1.2	18
78	Immuno-oncology combinations: raising the tail of the survival curve. <i>Cancer Biology and Medicine</i> , 2016, 13, 171-193.	1.4	98
79	Emerging strategies for the treatment of advanced small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E1249-E1253.	0.6	1
80	CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 697-699.	7.7	30
81	PARP inhibitors: the race is on. <i>British Journal of Cancer</i> , 2016, 114, 713-715.	2.9	135
82	Development of molecularly targeted agents and immunotherapies in small cell lung cancer. <i>European Journal of Cancer</i> , 2016, 60, 26-39.	1.3	28
83	Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 2431-2432.	0.8	6
84	A study of motivations and expectations of patients seen in phase 1 oncology clinics. <i>Cancer</i> , 2016, 122, 3501-3508.	2.0	24
85	Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792). <i>Cancer Research</i> , 2016, 76, CT012-CT012.	0.4	12
86	A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4203-4203.	0.6	15
87	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. <i>BMC Research Notes</i> , 2015, 8, 688.	0.6	4
88	Drugging PI3K in cancer: refining targets and therapeutic strategies. <i>Current Opinion in Pharmacology</i> , 2015, 23, 98-107.	1.7	186
89	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , 2015, 21, 4586-4596.	3.2	171
90	Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity. <i>Molecular Cancer Therapeutics</i> , 2015, 14, PR14-PR14.	1.9	14

#	ARTICLE	IF	CITATIONS
91	Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. <i>Clinical Cancer Research</i> , 2014, 20, 5672-5685.	3.2	66
92	Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 285.	0.4	30
93	Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways. <i>Journal of Clinical Oncology</i> , 2013, 31, 1592-1605.	0.8	249
94	Intratumor Heterogeneity: Seeing the Wood for the Trees. <i>Science Translational Medicine</i> , 2012, 4, 127ps10.	5.8	443
95	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 549-573.	4.2	96
96	PI3K&A€AKT&A€mTOR inhibitors for the systemic treatment of endometrial cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2012, 7, 421-430.	0.4	1
97	Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1293-1304.	1.9	23
98	Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 31-49.	157.7	178
99	Envisioning the future of early anticancer drug development. <i>Nature Reviews Cancer</i> , 2010, 10, 514-523.	12.8	262
100	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval. <i>Journal of Clinical Oncology</i> , 2010, 28, 2512-2519.	0.8	877
101	Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from<i>BRCA</i>Mutation Carriers. <i>New England Journal of Medicine</i> , 2009, 361, 123-134.	13.9	3,312
102	Adjuvant Therapy of Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 120-130.	0.9	14